Posts Tagged ‘Phase’

Targacept Announces Initiation Of Phase 2 Studies Of TC-6987 In Asthma And Type 2 Diabetes
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes. TC-6987 is a modulator of the alpha7 neuronal nicotinic receptor and was discovered by Targacept …

Read more on Medical News Today

Nutrition Rating Enhancing Front-Of-Package Nutrition Rating Systems And Symbols: Phase 1
Nutrition rating systems and symbols on the fronts of food packaging would be most useful to shoppers if they highlighted four nutrients of greatest concern – calories, saturated fat, trans fat, and sodium – says a new report from the Institute of Medicine. These food components are routinely overconsumed and associated most strongly with diet-related health problems affecting many Americans …

Read more on Medical News Today

Positive top-line results from Phenomix’ Phase 3 trial of dutogliptin for Type 2 diabetes mellitus
Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix’ internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.

Accumetrics completes enrollment phase of GRAVITAS clinical trial
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.

Biodel’s VIAject insulin Phase 3 study results to be presented at international diabetes conference in Basel
Biodel, Inc. announced today that its chief executive officer, Dr. Sol Steiner, will present results from the company’s two Phase 3 studies with VIAject® ultra-rapid-acting recombinant human insulin in a platform presentation at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland, on Friday, February 12, 2010, at 1pm central European time.